Julie Chang

7PUBLICATIONS
47CO-AUTHORS
Molecular targetsPredictive and prognostic markersCancer therapy (excl. chemotherapy and radiation therapy)BiomaterialsMicroelectromechanical systems (MEMS)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|Jul 09, 2025
Single-Agent Divarasib in Patients With <i>KRAS G12C</i>-Positive Non-Small Cell Lung Cancer: Long-Term Follow-Up of a Phase I Study.

Adrian G Sacher, Wilson H Miller, Manish R Patel

|Jul 12, 2024
Circulating Tumor DNA Dynamics Reveal KRAS G12C Mutation Heterogeneity and Response to Treatment with the KRAS G12C Inhibitor Divarasib in Solid Tumors.

Yoonha Choi, Neekesh V Dharia, Tomi Jun

|Dec 05, 2023
Divarasib plus cetuximab in KRAS G12C-positive colorectal cancer: a phase 1b trial.

Jayesh Desai, Guzman Alonso, Se Hyun Kim

|Nov 13, 2023
Cell volume expansion and local contractility drive collective invasion of the basement membrane in breast cancer.

Julie Chang, Aashrith Saraswathibhatla, Zhaoqiang Song

|Jul 19, 2019
Beyond proteases: Basement membrane mechanics and cancer invasion.

Julie Chang, Ovijit Chaudhuri

Pageof 2